Optimizing the Medical Management of IBD by Primary Care Clinicians
Release Date: August-05-14
Credit Expiration Date: August-05-15
This activity is intended for internal medicine physicians and other primary care clinicians involved in the care of patients with IBD.
Physicians: 1.25 AMA PRA Category 1 Credit TM
Ulcerative colitis (UC) and Crohn’s disease (CD), which together are referred to as inflammatory bowel disease (IBD), are complex conditions. Because of the complicated nature of IBD, diagnosis and treatment is impeded by numerous obstacles that can affect diagnostic accuracy and quality of care. In addition, new data available to clinicians are revising the management paradigm for IBD. These new data can be used to bridge the gaps in knowledge and clinical practice among clinicians who diagnose and treat IBD, and the data also present opportunities to improve practice patterns. The goal of this continuing education activity is to enhance competency and build additional skills among internists in the treatment and management of this disease, ultimately improving outcomes for patients with IBD.
Gary R. Lichtenstein, MD
Director, Center for IBD, University of Pennsylvania Health System
Professor of Medicine
University of Pennsylvania School of Medicine
Bret Lashner, MD
Professor of Medicine
Center for Inflammatory Bowel Disease
Department of Gastroenterology
Digestive Disease Institute
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Gary Lichtenstein, MD has disclosed the following:
Consultant/Advisor: Abbott Corporation/AbbVie, Alaven, Elan, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Millennium Pharmaceuticals, Ono Pharmaceuticals, Pfizer, Prometheus Laboratories, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda, UCB, and Warner Chilcotte
Research/Grant Support: Bristol-Myers Squibb, Ferring, Janssen Orthobiotech, Prometheus Laboratories, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UCB, and Warner Chilcotte
Royalties/Patents: SLACK, Inc.
Bret Lashner, MD has nothing to disclose.
Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 70% or better on the post-test.
The online activity will take approximately 75 minutes to complete.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5588-15-T.
This educational activity is supported by independent medical education grants from AbbVie and Shire.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, AbbVIe, or Shire. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.